Impact of Postoperative Treatment with Recombinant Human Growth Hormone and Hypocaloric Parenteralnutrition on Gastrointestinal Cancer

刘权焰,薛平惠,刘志苏
DOI: https://doi.org/10.11569/wcjd.v12.i11.2651
2005-01-01
Abstract:Objective To study the role of recombined human growth hormone (r-hGH) and (hypocaloric) parenteral nutrition (HPN) in the post-operative patients of gastrointestinal cancer. Methods A prospective, randomized, double-blinded clinical trial was performed in one hundred post-operative patients of gastrointestinal cancer. The r-hGH group was given HPN plus r-hGH for 7 days, and the control group was given standard total parenteral nutrition for 6 days. The levels of protein, immune function, nitrogen balance, infection related complications, days of hospital stay, survival rate and recurrence rate were compared between two groups. Results The physical signs, liver and kidney function test, side effect, serum level of lipid, hemoglobin, white blood cell and platelet count were no significant difference between two groups after 6 days′ post-operative treatment. The level of serum total protein, IgG, IgA, IgM, CD~+_3 and CD~+_4 T cells in the r-hGH group were not different on post-operative day 7 compared with those of pre-operation ( P 0.05). All of the indexes in control group were lower on post-operative day 7 than those of pre-operation. The levels of pre-albumin,transferrin, fibronectin, IgG,IgM, CD~+_3, CD~+_4 T cells and nitrogen balance in the study group were significantly higher than those of control group.Negative nitrogen balance began to be positive in the study group on the post-operative day 7. However, the nitrogen balance in the control group was still negative on the post-operative day 10. The duration of hospitalization in the r-hGH group was shorter than that of the control group. The 1-year, 2-year and 3-year survival rates and recurrence rate were not different between two groups.(Conclusions) The post-operative short-term use of the r-hGH plus HPN in patients with excisable gastrointestinal cancer is safe, effective and benefit for the post-operative recovery.
What problem does this paper attempt to address?